

March 14, 2023

Tenshi Kaizen Private Limited: Update on Material Event

Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Outstanding
Long Term – Term Loan	90.00	90.00	[ICRA]BB+(CE) (Stable)
Total	90.00	90.00	

*Instrument details are provided in Annexure I

Rating Without Explicit Credit Enhancement	[ICRA]BB-
---------------------------------------------------	------------------

Note: The (CE) suffix mentioned alongside the rating symbol indicates that the rated instrument/facility is backed by some form of explicit credit enhancement. This rating is specific to the rated instrument/facility, its terms and structure and does not represent ICRA's opinion on the general credit quality of the entity concerned. The last row in the table above also captures ICRA's opinion on the rating without factoring in the explicit credit enhancement.

Rationale

On March 02, 2023, ICRA was informed that Tenshi Life Sciences Private Limited (Tenshi Life or the company), the parent of Tenshi Kaizen Private Limited (Kaizen) has received the final order from National Company Law Tribunal (NCLT) pertaining to the company's amalgamation with Tenshi Pharmaceuticals Private Limited (Tenshi Pharma).

The rating assigned to Kaizen is based on the strength of the corporate guarantee provided by Tenshi Life (rated [ICRA]BB+ (Stable)/[ICRA]A4+).

ICRA takes note of the aforementioned update on amalgamation of Tenshi Life with Tenshi Pharma. ICRA will continue to engage with the company to evaluate the impact of the aforementioned update on its credit profile. Further, ICRA will continue to monitor these developments and take appropriate rating action as and when more clarity emerges.

Please refer to the following link for the previous detailed rationale that captures the key rating drivers and their description, the liquidity position, rating sensitivities and key financial indicators: [Click here](#)

Analytical approach

Analytical Approach	Comments
Applicable Rating Methodologies	Corporate Credit Rating Methodology Rating Methodology for Entities in the Pharmaceutical Industry Approach for rating debt instruments backed by third-party explicit support
Parent/Group Support	The assigned rating is based on the unconditional and irrevocable corporate guarantee extended by Tenshi Life.
Consolidation/Standalone	The rating is based on the standalone financial statements of the rated entity.

About the company

Tenshi Kaizen Private Limited formerly known as Higher Pharmatech Private Limited was incorporated on April 02, 2007. Kaizen is backed by promoters, Mr. Arun Kumar, and Mr. Venkat S Iyer, who have wide knowledge of the pharmaceutical industry and a track record of incubating and developing pharmaceutical businesses. Kaizen has a R&D and manufacturing facility in Harohalli, Bangalore. The construction of probiotics manufacturing facility in Mysore and the plans for probiotics manufacturing is currently kept on hold. Kaizen also had a formulation facility in New Jersey which was expected to commence operations from FY2022, however, the same was getting delayed due to Covid restrictions as machineries could not be installed. The same is expected to be liquidated in the near term and the machineries are now being transferred to Bangalore facility (wherein expansion is being undertaken adjacent to the existing factory site).

Key financial indicators

Kaizen Standalone	FY2021	FY2022
Operating income (Rs. crore)	28.6	48.7
PAT (Rs. crore)	-1.9	-24.1
OPBDIT/OI (%)	41.1%	-13.2%
PAT/OI (%)	-6.7%	-49.6%
Total outside liabilities/Tangible net worth (times)	0.7	1.4
Total debt/OPBDIT (times)	9.4	-35.1
Interest coverage (times)	1.4	-0.6

PAT: Profit after Tax; OPBDITA: Operating Profit before Depreciation, Interest, Taxes and Amortisation; All Amounts as per ICRA calculations

Tenshi Life Consolidated	FY2021	FY2022
Operating income (Rs. crore)	153.8	280.1
PAT (Rs. crore)	-100.5	-237.7
OPBDITA/OI (%)	-7.4%	-40.9%
PAT/OI (%)	-65.4%	-84.9%
Total outside liabilities/Tangible net worth (times)	1.6	2.2
Total debt/OPBDITA (times)	-96.0	-9.8
Interest coverage (times)	-0.2	-1.3

PAT: Profit after Tax; OPBDITA: Operating Profit before Depreciation, Interest, Taxes and Amortisation; All Amounts as per ICRA calculations

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

Instrument	Type	Current rating (FY2023)				Chronology of rating history for the past 3 years		
		Amount Rated (Rs. crore)	Amount outstanding as of Mar 31, 2022 (Rs. crore)	Date & Rating in FY2023		Date & Rating in FY2022	Date & Rating in FY2021	Date & Rating in FY2020
				Mar 14, 2023	July 28, 2022			
1 Term Loan	Long Term	90.00	49.10	[ICRA]BB+(CE) (Stable)	[ICRA]BB+(CE) (Stable)	[ICRA]BBB-(CE)(Negative)	--	[ICRA]BBB-(CE)(Negative)

Amount in Rs. Crore

Complexity level of the rated instruments

Instrument	Complexity Indicator
Term Loan	Simple

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional, or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click Here](#)

Annexure I: Instrument details

ISIN No	Instrument Name	Date of Issuance	Coupon Rate	Maturity Date	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Term Loans	FY2018	10.0%	FY2025	90.00	[ICRA]BB+(CE) (Stable)

Source: Company; Note: Amounts in Rs. crore

[Please click here to view details of lender-wise facilities rated by ICRA](#)

Annexure II: List of entities considered for consolidated analysis – Not applicable

ANALYST CONTACTS

Shamsher Dewan

+91 124 4545 5328

shamsherd@icraindia.com

Kinjal Shah

+91 22 6114 3442

kinjal.shah@icraindia.com

Mythri Macherla

+91 80 4332 6407

mythri.macherla@icraindia.com

Seetha Pillai

+91 80 4332 6411

seetha.pillai@icraindia.com

RELATIONSHIP CONTACT

Jayanta Chatterjee

+91 80 4332 6401

jayantac@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

Helpline for business queries

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited



Registered Office

B-710, Statesman House, 148, Barakhamba Road, New Delhi-110001
Tel: +91 11 23357940-45



Branches



© Copyright, 2023 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.